Inventor · disambiguated record
Ding-Quan Qian
Also filed as: QIAN DING-QUAN
48 granted patents·28 pending applications·815 citations·filing 2005–2025
98Inventor score
Top patents by PatentIndex Score
76 records- 0199US7767675B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsINCYTE CORP·Filed 2007·Granted Aug 3, 2010·85 cites·85 claims
- 0298US11673883B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·12 cites·29 claims
- 0398US11339149B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted May 24, 2022·24 cites·20 claims
- 0498US11014923B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2020·Granted May 25, 2021·22 cites·32 claims
- 0598US10947230B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2019·Granted Mar 16, 2021·26 cites·44 claims
- 0698US10800768B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Oct 13, 2020·30 cites·18 claims
- 0798US10738048B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Aug 11, 2020·28 cites·21 claims
- 0898US10435392B2Bipyrazole derivatives as JAK inhibitorsINCYTE CORP·Filed 2018·Granted Oct 8, 2019·18 cites·28 claims
- 0998US9533984B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2014·Granted Jan 3, 2017·42 cites·6 claims
- 1098US9266892B2Fused pyrazoles as FGFR inhibitorsINCYTE CORP·Filed 2013·Granted Feb 23, 2016·40 cites·40 claims
- 1197US11667635B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2021·Granted Jun 6, 2023·7 cites·22 claims
- 1297US11591318B2Bipyrazole derivatives as JAK inhibitorsINCYTE CORP·Filed 2021·Granted Feb 28, 2023·6 cites·19 claims
- 1397US11001571B2Bipyrazole derivatives as JAK inhibitorsINCYTE CORP·Filed 2019·Granted May 11, 2021·15 cites·16 claims
- 1497US10851105B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2019·Granted Dec 1, 2020·27 cites·27 claims
- 1597US10806785B2Immunomodulator compounds and methods of useINCYTE CORP·Filed 2017·Granted Oct 20, 2020·32 cites·17 claims
- 1697US10214528B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2018·Granted Feb 26, 2019·35 cites·20 claims
- 1797US9890156B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2016·Granted Feb 13, 2018·40 cites·8 claims
- 1897US9382231B2Bipyrazole derivatives as JAK inhibitorsINCYTE CORP·Filed 2014·Granted Jul 5, 2016·40 cites·30 claims
- 1997US8461330B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsZHUO JINCONG·Filed 2010·Granted Jun 11, 2013·40 cites·25 claims
- 2096US9527835B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Dec 27, 2016·25 cites·22 claims
- 2196US9493450B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Nov 15, 2016·26 cites·33 claims
- 2296US7776874B2Amido compounds and their use as pharmaceuticalsINCYTE CORP·Filed 2008·Granted Aug 17, 2010·27 cites·24 claims
- 2396US7304081B2Amido compounds and their use as pharmaceuticalsINCYTE CORP·Filed 2005·Granted Dec 4, 2007·42 cites·25 claims
- 2495US11905275B2Bipyrazole derivatives as JAK inhibitorsINCYTE CORP·Filed 2023·Granted Feb 20, 2024·2 cites·29 claims
- 2595US9944645B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsINCYTE HOLDINGS CORP·Filed 2016·Granted Apr 17, 2018·15 cites·15 claims
- 2695US8058288B2Amido compounds and their use as pharmaceuticalsYAO WENQING·Filed 2010·Granted Nov 15, 2011·22 cites·35 claims
- 2794US11673894B2Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·4 cites·25 claims
- 2894US11472791B2Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Oct 18, 2022·7 cites·31 claims
- 2994US9126927B2Amido compounds and their use as pharmaceuticalsYAO WENQING·Filed 2011·Granted Sep 8, 2015·20 cites·33 claims
- 3094US7683060B2Triazolotriazines as kinase inhibitorsINCYTE CORP·Filed 2007·Granted Mar 23, 2010·25 cites·152 claims
- 3193US11981671B2Bicyclic pyrazolyl amines as CDK2 inhibitorsINCYTE CORP·Filed 2022·Granted May 14, 2024·2 cites·58 claims
- 3293US11976073B2Bicyclic amines as CDK2 inhibitorsINCYTE CORP·Filed 2022·Granted May 7, 2024·2 cites·65 claims
- 3393US11851426B2Bicyclic amines as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Dec 26, 2023·3 cites·20 claims
- 3492US10738052B2Imidazotriaines and imidazopyrimidines as kinase inhibitorsINCYTE CORP·Filed 2018·Granted Aug 11, 2020·3 cites·18 claims
- 3589US9957229B2Amido compounds and their use as pharmaceuticalsINCYTE CORP·Filed 2017·Granted May 1, 2018·4 cites·6 claims
- 3689US2025223291A1Imidazotriazines and imidazopyrimidines as kinase inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 3787US12247020B2Bipyrazole derivatives as JAK inhibitorsINCYTE CORP·Filed 2024·Granted Mar 11, 2025·0 cites·20 claims
- 3885US8143251B2Triazolotriazines as kinase inhibitorsZHUO JINCONG·Filed 2011·Granted Mar 27, 2012·7 cites·17 claims
- 3984US7915408B2Triazolotriazines as kinase inhibitorsINCYTE CORP·Filed 2010·Granted Mar 29, 2011·6 cites·29 claims
- 4082US12084449B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsINCYTE CORP·Filed 2022·Granted Sep 10, 2024·0 cites·1 claims
- 4180US2023357255A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2023·Application pending·0 cites
- 4280US2025206726A1Bipyrazole derivatives as jak inhibitorsINCYTE CORP·Filed 2025·Application pending·0 cites
- 4379US12466828B2Bicyclic amines as CDK2 inhibitorsINCYTE CORP·Filed 2023·Granted Nov 11, 2025·0 cites·47 claims
- 4477US8110581B2Lactam compounds and their use as pharmaceuticalsYAO WENQING·Filed 2008·Granted Feb 7, 2012·2 cites·22 claims
- 4576US2025325660A1Immunomodulator compounds and methods of useINCYTE CORP·Filed 2025·Application pending·0 cites
- 4675US2025313567A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2025·Application pending·0 cites
- 4774US11261191B2Imidazotriaines and imidazopyrimidines as kinase inhibitorsINCYTE CORP·Filed 2020·Granted Mar 1, 2022·0 cites·21 claims
- 4871US8193207B2Lactam compounds and methods of using the sameZHUO JINCONG·Filed 2006·Granted Jun 5, 2012·1 cites·56 claims
- 4970US2020181077A1Cyclopropylamines as lsd1 inhibitorsINCYTE CORP·Filed 2019·Application pending·0 cites
- 5070US2023226062A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Application pending·0 cites
Showing the top 50 of 76 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ding-Quan Qian files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →